These two firms have successful drugs and could make nice additions for larger companies.
The oncology company already has risen significantly this year, but its charts indicate the rally could continue.
Initial inquiry into deal showed it could remove what might be most significant competitive threat to Illumina.
Takeover action in biotech and speculative interest in small caps kept things interesting during an otherwise sleepy Monday, as everyone awaits Wednesday's Fed decision.
Appetite is growing for UNFI as the company is cutting debt and surpassing consensus earnings' estimates.
A report says the biotechnology company is exploring options including a potential sale amid interest from pharmaceutical companies looking to expand in gene therapy.
Treatment for rare lung disease misses test goals, sending shares into tailspin.
The stocks of these two developmental concerns have slid recently, but there are reasons to believe they will improve.
Shares of Spark Therapeutics slide amid a second regulatory-related delay of its $4.3 billion deal with Swiss pharmaceuticals group Roche Holdings AG.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.